Literature DB >> 2450207

Interferons in host defense.

C R Faltynek1, J J Oppenheim.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 2450207     DOI： 10.1093/jnci/80.3.151

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  10 in total

1.  Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Authors:  Z Gazit; D W Weiss; D Shouval; M Yechezkeli; V Schirrmacher; M Notter; J Walter; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 2.  Interaction of interferon with other cytokines.

Authors:  G Opdenakker; Y Cabeza-Arvelaiz; J Van Damme
Journal:  Experientia       Date:  1989-06-15

3.  Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.

Authors:  E Kedar; Y Rutkowski; B Leshem
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Immunoreactive alpha interferon in cervical flat koilocytic lesions and intraepithelial neoplasia.

Authors:  C J Stewart; M A Farquharson; A M McNicol; A K Foulis
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

5.  Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.

Authors:  G Gasparini; S Dal Fior; F Pozza; G A Panizzoni; S Favretto; D D Von Hoff
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

6.  Endogenous interferon alpha/beta produced by Kupffer cells inhibits interleukin-1, tumor necrosis factor alpha production and interleukin-2-induced activation of nonparenchymal liver cells.

Authors:  S P Tzung; S A Cohen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Augmented production of granulocyte-macrophage colony-stimulating factor and alpha/beta interferon in mice inoculated with heat-killed Corynebacterium liquefaciens.

Authors:  T Yoshida; T Hotta; K Shimokata; M Ichihara; K Isobe; I Nakashima
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

8.  Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.

Authors:  B Fiorentino; P Di Stefano; C Giuliani; C Amatetti; N Tinari; C Natoli; C Garufi; S Iacobelli
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

9.  Immune homeostasis and regulation of the interferon pathway require myeloid-derived Regnase-3.

Authors:  Annalisa Schaub; Alisha N Jones; Christian Schulz; Mathias Heikenwalder; Matthias von Gamm; Christine Wolf; Gesine Behrens; Johannes Lichti; Katharina Essig; Anna Macht; Joachim Pircher; Andreas Ehrlich; Kathrin Davari; Dhruv Chauhan; Benjamin Busch; Wolfgang Wurst; Regina Feederle; Annette Feuchtinger; Matthias H Tschöp; Caroline C Friedel; Stefanie M Hauck; Michael Sattler; Arie Geerlof; Veit Hornung; Vigo Heissmeyer; Elke Glasmacher
Journal:  J Exp Med       Date:  2019-05-24       Impact factor: 14.307

10.  High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity.

Authors:  Y Tanio; M Watanabe; T Osaki; I Tachibana; I Kawase; T Kuritani; S Saito; T Masuno; N Kodama; K Furuse
Journal:  Jpn J Cancer Res       Date:  1992-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.